Delivery Order SPE2DB24D9223-SPE2DB25FKEAF

Award Date 1/15/25
Potential Completion Date 2/6/25
Potential Value $25K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $32,816.60 firm fixed-price delivery order contract is for the supply of Keytruda 100 mg/4 ml vial 4 ml, a specialized oncology medication. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue...
This federal contract award is a delivery order for KEYTRUDA 100 MG/4 ML VIAL 4ML, awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $24,568.74 firm fixed-price contract has an ultimate completion date of March 24, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $77,505.20 firm fixed-price delivery order is for the supply of 4560257909 KEYTRUDA 100 MG/4 ML VIAL 4ML, a specialized oncology medication. This award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) between DMS Pharmaceutical Group and the DLA under the SPE2DB program, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $40,947.80 firm fixed-price delivery order is for the supply of KEYTRUDA 100 MG/4 ML VIAL 4ML, a specialized oncology medication. The award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. This IDC enables...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $4,094.78 firm fixed-price delivery order is for the supply of 4,567,057,215 units of the prescription drug Keytruda (100 mg/4 ml vial, 4 ml). This award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program,...
This federal contract award was issued by the Defense Logistics Agency (DLA), a defense agency, to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $120,327.60 firm fixed-price delivery order contract is for the supply of Keytruda 100 mg/4 ml vials. The contract has an ultimate completion date of December 30, 2024. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under...
This federal contract award, valued at $160,571.40, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of KEYTRUDA 100 MG/4 ML VIAL 4ML, with an ultimate completion date of August 12, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $126,972.12 firm fixed-price delivery order is for the supply of KEYTRUDA 100 MG/4 ML VIAL 4ML, a specialty oncology medication. This award is issued under a larger Indefinite Delivery Contract (IDC) with DMS Pharmaceutical Group valued at $499,999,999, which enables the DLA to issue delivery...
This federal contract award, valued at $41,020.75, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of Keytruda 100 mg/4 ml vial 4 ml, a specialized oncology medication. The contract is not associated with any set-aside designation, allowing DMS Pharmaceutical Group to leverage its status as a woman-owned small...
This federal contract award, valued at $89,292.48, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of Keytruda, a specialty oncology medication, with an ultimate completion date of April 18, 2022. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the...
  • SPE2DB24D9223
    Indefinite Delivery Contract
  • SPE2DB24D9223-SPE2DB25FKEAF
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $24,568.74 firm fixed-price delivery order is for the supply of KEYTRUDA 100 MG/4 ML VIAL 4ML, a specialized oncology medication.

DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a comprehensive range of pharmaceutical products to support the medical supply needs of military health facilities. This contract award is not associated with any set-aside designations, allowing DMS Pharmaceutical Group to leverage its woman-owned small business status to secure direct federal contracts across various medical product categories. The contract has a period of performance through February 6, 2025.

Generated 4/17/25, 8:50 AM